Heart Failure
Heart Failure
Advertisement
Rob DillardHeart Failure | February 21, 2025
Certain athletes with CVD abnormalities may be able to safely participate in competitive sports.
Read More
CardioNerdsCardioNerds | February 18, 2025
The CardioNerds and expert faculty discuss a complicated case of ventricular tachycardia.
Rob DillardHeart Failure Guidelines | February 12, 2025
The CardioNerds and Dr. Robert Mentz discuss the important steps in treating HF with mineralocorticoid antagonists.
CardioNerdsCardioNerds | February 5, 2025
Dr. Kevin Alexander speaks with The CardioNerds about the importance of providing swift treatment to patients with ATTR-CM.
CardioNerdsCardioNerds | February 5, 2025
The CardioNerds, Dr. Alexander discuss how acoramidis therapy works, and details data Dr. Alexander presented at AHA 2024.
Kevin M. Alexander, MDCardioNerds | February 5, 2025
Dr. Georgia Vasilakis Tsatiris of The CardioNerds speaks to Dr. Kevin Alexander about the impact of ATTR-CM.
Rob DillardHeart Failure Guidelines | January 29, 2025
The CardioNerds in tandem with Dr. Clyde Yancy analyze a case of an 80-year-old man with heart failure.
CardioNerdsHeart Failure Guidelines | January 22, 2025
The CardioNerds and expert faculty Dr. Shelley Zieroth analyze a patient's heart failure classification.
Rob DillardCardiology | January 21, 2025
The FDA recently announced a first time proposed rule which would require the tobacco industry to lower nicotine levels.
CardioNerdsHeart Failure Guidelines | January 15, 2025
The CardioNerds and expert faculty Dr. Mark Drazner assess a woman's heart failure status.
CardioNerdsCardioNerds | February 18, 2025
The CardioNerds and colleagues review the differential diagnosis for peripartum cardiomyopathy.
CardioNerdsCardioNerds | February 18, 2025
The CardioNerds discuss a case involving a patient who presented with stress cardiomyopathy leading to cardiogenic shock.
Rob DillardAHA 2024: CardioNerds | November 27, 2024
The U.S. FDA recently approved Attruby (acoramidis) for adults with ATTR-CM to reduce cardiovascular death, hospitalization.
Amit Goyal, MDAHA 2024: CardioNerds | November 26, 2024
A study highlights the significant HCRU and costs associated with ATTR-CM.
Amit Goyal, MDAHA 2024: CardioNerds | November 26, 2024
Promising long-term outcomes from the ongoing OLE of the ATTRibute-CM trial highlight the efficacy of acoramidis.
Rob DillardAHA 2024: CardioNerds | November 26, 2024
A case study highlights the importance of avoiding anchoring bias in the diagnosis of cardiac amyloidosis.
Rob DillardAHA 2024: CardioNerds | November 26, 2024
The diagnosis of AL amyloidosis requires a high index of suspicion to render a prompt diagnosis and appropriate treatment.
Rob DillardAHA 2024: CardioNerds | November 20, 2024
A study further supports the efficacy of acoramidis in the treatment of people with ATTR-CM.
Rob DillardAHA 2024: CardioNerds | November 15, 2024
People with amyloidosis have a significantly higher prevalence of atrial fibrillation.
Rob DillardAHA 2024: CardioNerds | November 15, 2024
An AI model for detecting ATTR-CA yields solid diagnostic results.
Advertisement
Advertisement
Advertisement
Latest News

February 21, 2025